[The study of exocrine pancreas function by means of orally administered N-benzoyl-L-tyrosyl-praaminobenzoic acid (BT-PABA-test). Evaluation after 5 years clinical experience].
Exocrine pancreatic function was assessed in 588 persons by oral administration of 1 g of the chymotrypsin-labile peptide N-benzoyl-L-tyrosyl-paraaminobenzoic acid (BT-PABA) from 1974 to 1979. The BT-PABA-test was performed in 126 controls, 217 patients with pancreatic diseases, 196 patients with various non-pancreatic gastrointestinal diseases, 18 patients with renal diseases, and 31 patients with various other diagnoses. In 62 of 72 patients (86.1%) with chronic pancreatitis and in 19 of 25 patients with pancreatic carcinoma the excretion of paraaminobenzoic acid (PABA) in the urine was significantly less than in the controls. In contrast, 328 of 353 controls and patients with non-pancreatic diseases (92.9%) had a PABA excretion within normal limits. The sensitivity and specificity of the BT-PABA observed in this study is sufficient to detect moderate to severe disturbances of exocrine pancreatic function. The replacement of the liquid test-meal by a standard breakfast and additional meals taken during the collection period 4 or 5 hours after peptide intake did not influence the results of the BT-PABA-test, thus considerably simplifying the BT-PABA-test.
D010129:4-Aminobenzoic Acid / Q000652:urine; D000208:Acute Disease; D062365:Aminobenzoates; D006801:Humans; D010182:Pancreatic Diseases / Q000175:diagnosis*; D010190:Pancreatic Neoplasms / Q000175:diagnosis; D010195:Pancreatitis / Q000175:diagnosis
D062365:Aminobenzoates; D010129:4-Aminobenzoic Acid
Die Prüfung der exokrinen Pankreasfunktion mit oral verabreichter N-Benzoyl-L-Tyrosyl-Paraaminobenzoesäure (BT-PABA-test). Standortbestimmung nach 5 Jahren Erfahrung in der Klinik.